SGIOF News and Press, Shionogi & Co Ltd From 02/02/22

The following slide deck was published by Shionogi & Co., Ltd. in conjunction with their 2022 Q3 earnings call. For further details see: Shionogi & Co., Ltd. 2022 Q3 - Results - Earnings Call Presentation

ViiV Healthcare, majority-owned by GlaxoSmithKline (NYSE:GSK), announced that the FDA approved an every-two-month dosing regimen of the company’s HIV therapy Cabenuva, a combination of cabotegravir and rilpivirine. Cabotegravir and rilpivirine were developed by ViiV and Janssen unit of...

The FDA has approved ViiV Healthcare's Apretude (cabotegravir) as the first long-acting, injectable HIV treatment for pre-exposure prophylaxis (PrEP). Apretude can be administered as infrequently as six times per year. ViiV said that Vocabria (cabotegravir tablets) may be administered fo...

The following slide deck was published by Shionogi & Co., Ltd. in conjunction with their 2021 Q2 earnings call. For further details see: Shionogi & Co., Ltd. 2021 Q2 - Results - Earnings Call Presentation

ViiV Healthcare presents three-year results from the TANGO study at IDWeek 2021, held September 29 - October 3. Findings showed that the 2-drug regimen (2DR) Dovato (dolutegravir/lamivudine) continued to demonstrate non-inferior efficacy and a high barrier to resistance compared to continuati...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (NYSE:GSK), with Pfizer (NYSE:PFE) and Shionogi (OTCPK:SGIOY) as shareholders, announces an exclusive collaboration and license agreement with Shionogi & Co. for S-365598, a third-generation investigation...

The FDA has accepted and granted Priority Review for ViiV Healthcare's New Drug Application (NDA) for investigational, injectable cabotegravir long-acting for pre-exposure prophylaxis, or PrEP. The FDA has set a target approval date of 24 January 2022. If approved, cabotegravir would be the f...

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Total return for Harding Loevner International Equity Fund net of fees was 5.43% vs. MSCI All Country World ex-US ...

Shionogi & Co. (SGIOF): FY GAAP EPS of ¥395.28.Revenue of ¥297.17B (-10.9% Y/Y)Press Release For further details see: Shionogi & Co. reports FY results

The following slide deck was published by Shionogi & Co., Ltd. in conjunction with their 2021 Q3 earnings call. For further details see: Shionogi & Co., Ltd. 2021 Q3 - Results - Earnings Call Presentation